What role, if any, does systemic therapy have in the treatment of HCC amenable to definitive locoregional therapy?

Systemic therapy currently has no established role in patients with hepatocellular carcinoma (HCC) undergoing potentially curative locoregional therapy, including surgical resection or ablation. Active surveillance remains the standard of care after curative-intent treatment, and no perioperative sy...

For ablation, TACE and Y90, I traditionally hold back on systemic therapy so that I have something I can use if they develop metastases. Also, sorafenib has been not shown to be effective in the adjuvant setting so I apply that principle here. Bruix et al., PMID 26361969